MyoArete Overview
- Year Founded
-
2020
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
MyoArete General Information
Description
Developer of innovative therapies designed to cure Duchenne muscular dystrophy. The company's pipeline consists of utrophin upregulation-based products, low molecular weight organic compounds with pharmacological properties, and chemically synthesized, modified oligonucleotides, enabling DMD patients to increase utrophin expression.
Contact Information
Website
www.myoarete.comCorporate Office
- 750 Clinical Research Building (CRB)
- 415 Curie Boulevard
- Philadelphia, PA 19104-6085
- United States
Corporate Office
- 750 Clinical Research Building (CRB)
- 415 Curie Boulevard
- Philadelphia, PA 19104-6085
- United States
MyoArete Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 18-Sep-2024 | Completed | Out of Business | |||
| 1. Accelerator/Incubator | 01-Jan-2022 | Completed | Generating Revenue |
MyoArete FAQs
-
When was MyoArete founded?
MyoArete was founded in 2020.
-
Where is MyoArete headquartered?
MyoArete is headquartered in Philadelphia, PA.
-
What industry is MyoArete in?
MyoArete’s primary industry is Drug Discovery.
-
Is MyoArete a private or public company?
MyoArete is a Private company.
-
What is MyoArete’s current revenue?
The current revenue for MyoArete is .
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process